Residents of Medicine Hat and area will soon have a new location for blood and other laboratory testing. As part of the expansion of lab services in Medicine Hat, Alberta Health Services (AHS) has selected a location in a retail service centre, at 46 Carry Drive SE, to be the new site for community lab collections.
"The project is currently on time and on budget and is scheduled to be completed sometime in the fall of 2016. Then it will be ready to be opened in the spring of 2017," said Mauro Chies, Vice President of Clinical Support Services for AHS.
In addition to a waiting room, reception area and washrooms, there are 12 phlebotomy stations for taking blood specimens that will be sent to the laboratory at the hospital for testing. The Carry Drive location will also do ECGs and provide Holters — to continuously monitor various electrical activity of the cardiovascular system for at least 24 hours, said Ward.
The plan is to continue using Medicine Hat Diagnostic Laboratory until its contract expires in March 2017 and the transition to AHS is complete. If a decision is made to switch to Carry Drive sooner there would be absolutely "no interruption of servic" to the general public.
Iron Horse Dx announced that they have signed a nonexclusive license agreement with Euroimmun Medizinische Labordiagnostika AG (Lübeck, Germany) to launch the first biological diagnostic test for amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig’s disease.
Under the terms of agreement, Euroimmun AG, with distribution into over 130 countries, will have the nonexclusive rights to launch the ALS diagnostic assays as a CE marked product, while Iron Horse is launching the assay in the U.S. as a laboratory-developed test in CLIA-certified laboratories. Iron Horse is working in close collaboration with the ALS Association.
The ALS Test is based on over 20 years of research by Dr. Robert Bowser, President of Iron Horse Dx, and is shown to be 93% accurate (positive predictive value = 0.939 and negative predictive value = 0.917). According to Dr. Bowser, "We have come a long way in researching and understanding the complexities of ALS over the past few years. The ALS Test will benefit patients by aiding physicians to make a more rapid and definitive diagnosis, allowing more efficient clinical trials in particular in early phases of ALS, thereby shorting the time to finding a cure."
Theranos announced that the worst possible outcome of its troubled dealings with federal regulators had come to pass: the Centers for Medicare & Medicaid Services (CMS) had issued sanctions that, among other things, would revoke the company’s license to operate its Newark, California, laboratory and bar its high-profile CEO and founder Elizabeth Holmes from owning, operating, or directing any lab for at least two years.
In updated statements and information posted on its website, Theranos seemed to provide a clear, if not bold answer: Holmes will stay on at Theranos, even if it means abandoning its Arizona lab (where 90% of the company’s tests are processed) and focusing on its machines instead. "The clinical lab is just one of Theranos’ many opportunities to provide access to high-integrity, affordable and actionable health care information, and the company will continue to carry out its mission under the leadership of its founder and CEO, Elizabeth Holmes," the company stated. If Theranos intends to keep the Arizona lab running, it must split from Holmes before the sanctions take effect September 5.
Related Article: Arizona man says bum Theranos blood tests led to heart attack, files lawsuit